Clene

Clene FCF Growth

The Year-over-Year Free Cash Flow Growth of Clene (CLNN) as of Nov 16, 2026 is 12.91 %. In the previous year, Year-over-Year Free Cash Flow Growth was 30.03 % — a change of -57.00% (lower).

FCF Growth

12.91 %

YoY

-57.00%

Last updated:

Year-over-Year Free Cash Flow Growth of Clene is 2025 12.91 % . Year-over-Year Free Cash Flow Growth of Clene was 2024 30.03 % . It decreases by -57.00% lower compared to the previous year.

The Clene FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2019
-1,309.17 USD
Jan 1, 2020
-43.18 USD
Jan 1, 2021
-86.15 USD
Jan 1, 2022
-22.90 USD
Jan 1, 2023
30.98 USD
Jan 1, 2024
30.03 USD
Jan 1, 2025
12.91 USD
The Clene FCF Growth history
YEARFCF GrowthYoY
12.91 %-57.00%
30.03 %-3.05%
30.98 %-235.27%
-22.90 %-73.42%
-86.15 %+99.52%
-43.18 %-96.70%
-1,309.17 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc develops therapeutic products for neurodegenerative diseases, focusing on targeting energetic failure as a root cause. Its primary product CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by enhancing energy production and utilization. The company also develops CNM-ZnAg, a spectrum antiviral and antibacterial agent containing zinc and silver ions for infectious disease treatment and immune support, and CNM-AgZn17, a gel polymer suspension of zinc and silver for wound healing and infectious disease management. These products are intended for clinical development and eventual commercialization in the pharmaceutical market. Clene's target customers are patients suffering from neurodegenerative diseases and infectious conditions requiring antiviral, antibacterial, or wound healing solutions. The company's products aim to address unmet medical needs in these therapeutic areas by leveraging innovative nanocrystal and ion-based technologies. The firm operates within the biopharmaceutical sector, developing treatments that focus on cellular energy processes to provide neuroprotection and remyelination. The company generates revenue through the development and potential future commercialization of its drug candidates. CNM-Au8 targets neurodegenerative diseases by addressing energetic failure, while CNM-ZnAg and CNM-AgZn17 focus on infectious disease treatment and wound healing applications. These products are in clinical development stages, with the company seeking to advance them toward regulatory approval and market entry. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Year-over-Year Free Cash Flow Growth of Clene is 12.91 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Clene since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Clene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Clene

All Key Metrics — Clene